08:05 AM EDT, 06/27/2024 (MT Newswires) -- Lantheus Holdings ( LNTH ) said Thursday that it is acquiring global rights of Life Molecular Imaging's RM2, targeting the gastrin-releasing peptide receptor for prostate and breast cancers.
The company said it will make an upfront payment of $35 million as well as potential regulatory milestone payments plus royalties under the agreement.